IMA402

DRUG2 trials

Sponsors

Immatics Biotechnologies GmbH

Conditions

CancerRecurrent CancerRefractory CancerSolid Tumor, AdultSolid Tumors

Phase 1

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) targeting PRAME, as Monotherapy or in Combination with a Checkpoint Inhibitor in Patients with Recurrent and/or Refractory Solid Tumors

RecruitingCTIS2022-503133-54-00

Immatics Biotechnologies GmbHSolid Tumors

Start: 2023-08-09Target: 195Updated: 2025-12-15

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

RecruitingNCT05958121

Immatics Biotechnologies GmbHCancer, Recurrent Cancer, Refractory Cancer +1

Start: 2023-08-09End: 2027-09-01Target: 400Updated: 2026-07-01